Pryor Cashman represented Marina Biotech, Inc., a leading oligonucleotide-based drug discovery and development company (OTCQX: MRNA), in an exclusive licensing agreement with Monsanto Company for Marina Biotech’s delivery and chemistry technologies. 

Terms of the agreement, which was announced on May 8, 2012, were not disclosed.

Pryor Cashman Partners Larry Remmel, Stephen Goodman and Jeffrey Johnson, along with Counsel Michael T. Campoli, represented Marina Biotech in the transaction.